Log in

Twist Bioscience Stock Forecast, Price & News

+6.15 (+9.25 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $72.64
50-Day Range
MA: $65.50
52-Week Range
Now: $72.64
Volume489,153 shs
Average Volume563,638 shs
Market Capitalization$3.24 billion
P/E RatioN/A
Dividend YieldN/A
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.13 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:TWST



Sales & Book Value

Annual Sales$54.38 million
Book Value$4.63 per share


Net Income$-107,670,000.00
Net Margins-199.98%


Market Cap$3.24 billion
Next Earnings Date12/9/2020 (Estimated)
OptionableNot Optionable
+6.15 (+9.25 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

How has Twist Bioscience's stock price been impacted by Coronavirus (COVID-19)?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TWST shares have increased by 157.6% and is now trading at $72.64.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Twist Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Twist Bioscience

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, December 9th 2020.
View our earnings forecast for Twist Bioscience

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Corp (NASDAQ:TWST) posted its earnings results on Thursday, August, 6th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. The firm had revenue of $21.20 million for the quarter, compared to the consensus estimate of $13.67 million. Twist Bioscience had a negative net margin of 199.98% and a negative return on equity of 57.24%. Twist Bioscience's revenue for the quarter was up 55.9% compared to the same quarter last year.
View Twist Bioscience's earnings history

What price target have analysts set for TWST?

2 Wall Street analysts have issued 1-year price objectives for Twist Bioscience's stock. Their forecasts range from $42.00 to $42.00. On average, they anticipate Twist Bioscience's stock price to reach $42.00 in the next twelve months. This suggests that the stock has a possible downside of 42.2%.
View analysts' price targets for Twist Bioscience

Are investors shorting Twist Bioscience?

Twist Bioscience saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 4,200,000 shares, a drop of 12.5% from the August 15th total of 4,800,000 shares. Based on an average daily volume of 521,200 shares, the short-interest ratio is presently 8.1 days. Currently, 13.1% of the shares of the stock are sold short.
View Twist Bioscience's Short Interest

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include Pfizer (PFE), Crowdstrike (CRWD), Docusign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.Com (JD), Micron Technology (MU) and Square (SQ).

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Dr. Emily Marine Leproust, Co-Founder, Pres, CEO & Director (Age 45)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 64)
  • Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Gen. Counsel, Chief Ethics & Compliance Officer and Sec. (Age 56)
  • Mr. William Charles Banyai, COO & Director (Age 64)
  • Mr. Bill Peck, Chief Technology Officer (Age 59)

When did Twist Bioscience IPO?

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.05%), FMR LLC (3.59%), Bank of New York Mellon Corp (2.39%), Sumitomo Mitsui Trust Holdings Inc. (2.38%), Alyeska Investment Group L.P. (1.79%) and Victory Capital Management Inc. (1.46%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green and William Banyai.
View institutional ownership trends for Twist Bioscience

Which institutional investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., Cormorant Asset Management LP, William Blair Investment Management LLC, Asymmetry Capital Management L.P., Nicholas Investment Partners LP, Perceptive Advisors LLC, and Bank of America Corp DE. Company insiders that have sold Twist Bioscience company stock in the last year include Bill Peck, Emily M Leproust, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green, and William Banyai.
View insider buying and selling activity for Twist Bioscience

Which institutional investors are buying Twist Bioscience stock?

TWST stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Goldman Sachs Group Inc., Sumitomo Mitsui Trust Holdings Inc., Vanguard Group Inc., Wasatch Advisors Inc., Alyeska Investment Group L.P., Essex Investment Management Co. LLC, and Driehaus Capital Management LLC.
View insider buying and selling activity for Twist Bioscience

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $72.64.

How big of a company is Twist Bioscience?

Twist Bioscience has a market capitalization of $3.24 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is www.twistbioscience.com.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.